MicroRNA‑424 expression predicts tumor recurrence in patients with hepatocellular carcinoma following liver transplantation

Wu,Liming; Yang,Feibiao; Lin,Bingyi; Chen,Xinhua; Yin,Shengyong; Zhang,Feng; Xie,Haiyang; Zhou,Lin; Zheng,Shusen

doi:10.3892/ol.2018.8539

MicroRNA‑424 expression predicts tumor recurrence in patients with hepatocellular carcinoma following liver transplantation

Authors:
- Liming Wu
- Feibiao Yang
- Bingyi Lin
- Xinhua Chen
- Shengyong Yin
- Feng Zhang
- Haiyang Xie
- Lin Zhou
- Shusen Zheng
View Affiliations

Affiliations: Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, P.R. China, Key Lab of Combined Multi‑Organ Transplantation, Ministry of Public Health, Ningbo, Zhejiang 315100, P.R. China, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Ningbo, Zhejiang 315100, P.R. China
Published online on: April 19, 2018 https://doi.org/10.3892/ol.2018.8539
Pages: 9126-9132
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA‑424 (miR‑424) has previously been described as a biomarker of poor prognosis in patients with hepatocellular carcinoma (HCC). In the present study, the clinical significance of miR‑424 expression in predicting the rate of tumor recurrence in patients with HCC following liver transplantation (LT) was evaluated. miR‑424 expression in HCC samples from 121 patients undergoing LT was examined, and the associations between clinical parameters and patient tumor recurrence were evaluated. The miR‑424 expression level in cancer tissues was low compared with that in adjacent noncancerous tissues. Multivariate analyses revealed that low miR‑424 expression was an independent prognostic factor for tumor recurrence in patients with HCC following liver transplantation. Patients who no longer met the Milan criteria and had decreased miR‑424 expression levels exhibited earlier tumor recurrence following LT. In addition, the upregulation of miR‑424 expression significantly reduced the migration, invasion and proliferation of HCC cells. Similarly, the downregulation of miR‑424 in HCC cells significantly promoted the migration, invasion and proliferation of HCC cells.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
3	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
4	Dutkowski P, Linecker M, DeOliveira ML, Mullhaupt B and Clavien PA: Challenges to liver transplantation and strategies to improve outcomes. Gastroenterology. 148:307–323. 2015. View Article : Google Scholar : PubMed/NCBI
5	Ramesh H: Resection for hepatocellular carcinoma. J Clin Exp Hepatol. 4 Suppl 3:S90–S96. 2014. View Article : Google Scholar : PubMed/NCBI
6	Arzumanyan A, Reis HM and Feitelson MA: Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 13:123–135. 2013. View Article : Google Scholar : PubMed/NCBI
7	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
8	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
9	Ivkovic Catela T, Voss G, Cornella H and Ceder Y: microRNAs as cancer therapeutics: A step closer to clinical application. Cancer Lett. 407:113–122. 2017. View Article : Google Scholar : PubMed/NCBI
10	Hayes J, Peruzzi PP and Lawler S: microRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
11	Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A and Gennari L: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 334:693–699. 1996. View Article : Google Scholar : PubMed/NCBI
12	Xu X, Lu D, Ling Q, Wei X, Wu J, Zhou L, Yan S, Wu L, Geng L, Ke Q, et al: Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. Gut. 65:1035–1041. 2016. View Article : Google Scholar : PubMed/NCBI
13	Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, Liang TB and Wu LM: Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 85:1726–1732. 2008. View Article : Google Scholar : PubMed/NCBI
14	Yang Z, Zhou L, Wu LM, Lai MC, Xie HY, Zhang F and Zheng SS: Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol. 18:1243–1250. 2011. View Article : Google Scholar : PubMed/NCBI
15	Yang H, Zheng W, Shuai X, Chang RM, Yu L, Fang F and Yang LY: microRNA-424 inhibits Akt3/E2F3 axis and tumor growth in hepatocellular carcinoma. Oncotarget. 6:27736–27750. 2015.PubMed/NCBI
16	Zhang Y, Li T, Guo P, Kang J, Wei Q, Jia X, Zhao W, Huai W, Qiu Y, Sun L and Han L: miR-424-5p reversed epithelial-mesenchymal transition of anchorage-independent HCC cells by directly targeting ICAT and suppressed HCC progression. Sci Rep. 4:62482014. View Article : Google Scholar : PubMed/NCBI
17	Zhang F, Wu LM, Zhou L, Chen QX, Xie HY, Feng XW and Zheng SS: Predictive value of expression and promoter hypermethylation of XAF1 in hepatitis B virus-associated hepatocellular carcinoma treated with transplantation. Ann Surg Oncol. 15:3494–3502. 2008. View Article : Google Scholar : PubMed/NCBI
18	Wu LM, Zhang F, Xie HY, Xu X, Chen QX, Yin SY, Liu XC, Zhou L, Xu XB, Sun YL and Zheng SS: MMP2 promoter polymorphism (C-1306T) and risk of recurrence in patients with hepatocellular carcinoma after transplantation. Clin Genet. 73:273–278. 2008. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, Wu LM, Chen LM and Zheng SS: Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol. 29:1810–1816. 2012. View Article : Google Scholar : PubMed/NCBI
21	Kaiser J: The cancer stem cell gamble. Science. 347:226–229. 2015. View Article : Google Scholar : PubMed/NCBI
22	Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J and Busuttil RW: Recurrence of hepatocellular carcinoma following liver transplantation: A review of preoperative and postoperative prognostic indicators. Arch Surg. 143:182–188. 2008. View Article : Google Scholar : PubMed/NCBI
23	Schutte K, Schulz C, Link A and Malfertheiner P: Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J Hepatol. 7:139–149. 2015. View Article : Google Scholar : PubMed/NCBI
24	Kim JH, Sohn BH, Lee HS, Kim SB, Yoo JE, Park YY, Jeong W, Lee SS, Park ES and Kaseb A: Genomic predictors for recurrence patterns of hepatocellular carcinoma: Model derivation and validation. PLoS Med. 11:e10017702014. View Article : Google Scholar : PubMed/NCBI